Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | PARL | Q9H300 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclooctene SCHEMBL1299545 | 1.00 | MGLL (0.34) | MGLLPARLCA12CA1CA9 | |
| SCHEMBL57128 | 0.84 | PARL (0.38) | MGLLPARLCA12CA1CA9 | |
| Bicarbonate SCHEMBL28277654 | 0.82 | MGLL (0.36) | MGLLPARLCA12CA1CA9 | |
| Hno SCHEMBL15321628 | 0.80 | MGLL (0.36) | MGLLPARLCA12CA1CA9 | |
| SCHEMBL15321160 | 0.80 | MGLL (0.36) | MGLLPARLCA12CA1CA9 | |
| Oxirane SCHEMBL7945897 | 0.76 | MGLL (0.35) | MGLLPARLCA12CA1CA9 | |
| Methylene Chloride SCHEMBL28985432 | 0.76 | MGLL (0.36) | MGLLPARLCA12CA1CA9 | |
| Ethylene Glycol SCHEMBL2577550 | 0.76 | MGLL (0.34) | MGLLPARLCA12CA1CA9 | |
| SCHEMBL7450429 | 0.74 | MGLL (0.31) | MGLLPARL | |
| Diphenylether SCHEMBL1205239 | 0.73 | ALDH1A1 (0.46) | MGLLPARLALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030057-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230234065-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230065224-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES, RELATED SYSTEMS, DEVICES, AND METHODS FOR DETECTING, ANALYZING, QUANTIFYING, AND TESTING BIOLOGICS/GENETICS | PLEXIUM INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11577249-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4097232-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES, RELATED SYSTEMS, DEVICES, AND METHODS FOR DETECTING, ANALYZING, QUANTIFYING, AND TESTING BIOLOGICS/GENETICS | Plexium, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220025358-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. | 2022-01-27 | — | — | US | disclosed |
| US-20210394178-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. | 2021-12-23 | — | — | US | disclosed |
| US-11084037-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2021155040-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES, RELATED SYSTEMS, DEVICES, AND METHODS FOR DETECTING, ANALYZING, QUANTIFYING, AND TESTING BIOLOGICS/GENETICS | Plexium, Inc. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10981170-B2 | Oligonucleotide encoded chemical libraries | Plexium, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3687687-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3622968-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | The General Hospital Corporation (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2361098-B1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | MASSACHUSETTS GEN HOSPITAL (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190210018-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190093103-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. (US) | 2019-03-28 | — | — | US | disclosed |
| US-8900549-B2 | Compositions and methods for delivering a substance to a biological target | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION | 2013-11-14 | — | — | US | disclosed |
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2361098-A2 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | The General Hospital Corporation (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010051530-A2 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | THE GENERAL HOSPITAL CORPORATION (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268654-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | MGLL 2772/4885PARL 2812/4885CA12 216/4885 |
| US-20130302246-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET | FCER2, EPCAM, EPHA2 | MGLL 2772/4885PARL 2812/4885CA12 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.